2023 World Conference on Lung Cancer (Posters)-EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement

EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to analyze the frequency of EGFR mutations and ALK rearrangement in patients with pulmonary adenosquamous cell carcinoma (ASC). ASC is a rare subtype of non-small cell carcinoma composed of both squamous cell carcinoma and adenocarcinoma cells. The prognosis for ASC is very poor, and targeted therapies such as EGFR-TKIs and ALK inhibitors have shown effectiveness in treating patients with specific mutations or rearrangements.<br /><br />The researchers retrospectively analyzed patients with ASC who underwent surgical resection or biopsy between January 2012 and December 2021. EGFR mutations were assessed by direct sequencing or a PCR kit, while ALK rearrangement was assessed by fluorescence in situ hybridization (FISH).<br /><br />A total of 28 patients were included in the study, with a mean age of 75.9 years. Of these, 50% underwent surgical resection and the rest underwent percutaneous needle biopsy. The results showed that 17.9% of patients had EGFR mutations, including exon 19 deletions and L858R mutations. One patient had an exon 21 mutation, and there were no T790 M mutations. ALK rearrangement was found in 7% of cases.<br /><br />The authors concluded that the detection of somatic mutations, including EGFR and ALK, in patients with ASC is clinically important. The frequency of EGFR mutations in ASC is lower compared to conventional adenocarcinoma in the Asian population. ALK rearrangement, on the other hand, is less common in ASC.<br /><br />In summary, this study provides valuable insights into the frequency of EGFR mutations and ALK rearrangement in pulmonary ASC, highlighting the clinical significance of molecular testing in this subtype of lung carcinoma.

Asset Subtitle

Goohyeon Hong

Meta Tag

Speaker Goohyeon Hong

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

EGFR mutations

ALK rearrangement

pulmonary adenosquamous cell carcinoma

non-small cell carcinoma

targeted therapies

surgical resection

biopsy

exon 19 deletions

L858R mutations

molecular testing